CatSci

Executive Summary

CatSci is a UK-based contract research organization (CRO) specializing in integrated drug development for small molecules and complex synthetic medicines. Founded in 2011 by former AstraZeneca scientists, the company provides end-to-end services from early discovery through post-approval, leveraging deep expertise in chemistry, process development, and analytical sciences. Operating state-of-the-art laboratories across the UK and Europe, CatSci serves a diverse global client base of biotech and pharmaceutical companies. As a private, pre-clinical stage entity, its success is tied to its ability to secure long-term partnerships and expand its service offerings in a competitive CRO market. The company's strategic focus on complex synthetics and integrated solutions positions it well for growth, particularly as outsourced R&D continues to rise.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with a top-20 pharmaceutical company for multi-year integrated development program70% success
• Q2 2026Completion of new laboratory expansion in continental Europe to increase capacity and attract EU-based clients80% success
• Q4 2026Launch of a novel continuous manufacturing service line to address growing demand for efficient synthesis60% success